This is a multicenter, open-label, Phase 1 study to evaluate the safety, pharmacokinetic (PK), preliminary clinical activity, pharmacodynamic (PD), and biomarkers of AB521 as monotherapy for advanced solid tumor malignancies (dose escalation) and clear cell renal cell carcinoma (ccRCC) (dose expansion).
2 Primary · 4 Secondary · Reporting Duration: Up to 4 months
Experimental Treatment
86 Total Participants · 4 Treatment Groups
Primary Treatment: Cohort 3: Dose 3 · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: